|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-3-11
|
|
pubmed:abstractText |
The advent of new antiretrovirals has expanded the therapeutic options for multiple drug-resistant HIV-1 infection. The role of recycled nucleoside reverse transcriptase inhibitors (NRTIs) in this scenario remains uncertain.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1460-2091
|
|
pubmed:author |
pubmed-author:BlancoJosé RJR,
pubmed-author:BravoIsabelI,
pubmed-author:CaballeroEstrellaE,
pubmed-author:CamachoAngelaA,
pubmed-author:ClotetBonaventuraB,
pubmed-author:CurranAdrianA,
pubmed-author:DomingoPereP,
pubmed-author:FalcóVicençV,
pubmed-author:GayáFranciscoF,
pubmed-author:ImazArkaitzA,
pubmed-author:KarevA VAV,
pubmed-author:LlibreJosep MJM,
pubmed-author:MateoGraciaG,
pubmed-author:RiberaEstebanE,
pubmed-author:RiveroAntonioA,
pubmed-author:SantosJosé RJR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
358-62
|
|
pubmed:dateRevised |
2011-10-12
|
|
pubmed:meshHeading |
pubmed-meshheading:21172789-Adult,
pubmed-meshheading:21172789-Anti-HIV Agents,
pubmed-meshheading:21172789-CD4 Lymphocyte Count,
pubmed-meshheading:21172789-CD4-Positive T-Lymphocytes,
pubmed-meshheading:21172789-Drug Resistance, Multiple, Viral,
pubmed-meshheading:21172789-Female,
pubmed-meshheading:21172789-HIV Infections,
pubmed-meshheading:21172789-HIV-1,
pubmed-meshheading:21172789-Humans,
pubmed-meshheading:21172789-Male,
pubmed-meshheading:21172789-Middle Aged,
pubmed-meshheading:21172789-Nucleosides,
pubmed-meshheading:21172789-RNA-Directed DNA Polymerase,
pubmed-meshheading:21172789-Reverse Transcriptase Inhibitors,
pubmed-meshheading:21172789-Salvage Therapy,
pubmed-meshheading:21172789-Viral Load
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
|
|
pubmed:affiliation |
Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
